AGP Executive Report
Last update: 9 hours agoFDA & Mental Health: Definium Therapeutics’ DT120 (lysergide) won a second FDA Breakthrough Therapy designation for major depressive disorder, after Phase 3 Emerge results showed rapid, sustained MADRS improvement. Microbiome Trends: Probiotic supplement use surged in the US—up sharply for teens and adults—while fiber intake barely moved, raising questions about whether people are changing diets or just adding pills. Biopharma Compliance: DOJ says Veloxis ran a long kickback scheme to boost Envarsus XR prescriptions, settling for $46M+ and years of compliance oversight. Healthcare Policy/Regulation: FDA filled four senior roles permanently, including top drug and biologics leadership, aiming to stabilize the agency after earlier upheaval. Cancer Pipeline: Tyra Biosciences’ dabogratinib fell short in Phase 2 expectations, though related FGFR3-altered NMIBC data point to meaningful response rates at a 60 mg dose. Care Delivery & Workforce: Lifepoint Health is piloting AI to reduce nursing documentation burden and reprioritize patient assignments. AI in Biotech Ops: Industry leaders say AI is increasingly used for enrollment forecasting and manufacturing planning to cut rework and improve reliability. Clinical Innovation: UT Southwestern is using focused ultrasound for Parkinson’s tremors without incisions or implants. Mental Health Services: North Carolina is investing $1.9M to modernize and expand its clubhouse network for serious mental illness recovery.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
